Celator, Cephalon extend cancer research agreement
Celator Pharmaceuticals today announced that it has agreed with Cephalon, Inc. to extend an existing research agreement into the next phase of development. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.
Read more on News-Medical-Net
You must log in to post a comment.